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Decades of research have shed light on many aspects of T-cells,
spawning a myriad of diagnostic and therapeutic applications in
the process. Chief among those properties is the unique abil-
ity of T-cells to scan the intra-cellular protein content to detect
anomalies in tissues, be it the presence of pathogens or cellu-
lar transformation. The tri-partite interaction between the T-cell
receptor (TCR), its co-receptor CD4 or CD8, and peptide-major
histocompatibility (pMHC) ligands determines the outcome of
an encounter between a T-cell and an antigen presenting cell and
can result in ignorance or trigger a cellular activation program
central to adaptive immunity. Over the years, tremendous insights
into the rules that govern this interaction have been gained at
the molecular and cellular levels, resulting in the development
of technologies and tools that improve our understanding of the
dynamics of antigen-specific T-cell responses in vivo as well as
therapeutic modalities aimed at harnessing the power of T-cells
through vaccines, cellular therapies, and biologics. The selection
of 18 articles that constitute this Research Topic reflects these
advances in many ways and provides a snapshot of the current
focus in the field, with an emphasis on the efforts made in order
to translate our knowledge of T-cell biology into tools for therapy,
diagnosis, and immune-monitoring.
From a fundamental point of view two primary research arti-
cles examine how T-cells discriminate between pMHC antigens
and integrate signals that result in different cellular outcomes.
Schaft et al. tested a panel of altered peptide ligands of human
glycoprotein (gp)100 and identified a partial agonist that disso-
ciates signaling networks downstream of TCR triggering (1). The
altered peptide ligand they identified elicits cytotoxicity but negli-
gible or no cytokine secretion nor NFAT-mediated transcription,
an intriguing observation that appears related to the extent of
binding by TCR and CD8α and reveals the intricacies of signal
transduction downstream of the TCR. In an extensive study of
T-cell activation, van den Berg et al. examined the response of
a human CD8+ T-cell clone against several agonists of different
affinities for the TCR (2). Their results support a model of epitope
discrimination at the cellular level based on the integration of TCR
signals, whereby the sum of signals read by a T-cell determines the
functional response, rather than by the individual properties of
receptor–ligand interactions. These two reports further highlight
the analog nature of signal processing in T-cells, which enables
diverse functional outcomes based on the concatenation of input
signals rather than a binary response mediated via a simple on/off
switch mechanism.
Also in the domain of basic research the articles by Li et al. and
Szomolay et al. offer comprehensive insights into the roles of the
co-receptors CD4 and CD8. In the former article, the authors sum-
marize the literature on the structural and biophysical properties
of the pMHC/co-receptor interaction and discuss the implica-
tions on the topological organization of the entire antigen receptor
machinery on the T-cell membrane, a parameter that likely influ-
ences the initiation and transduction of TCR signals (3). Szomolay
et al. focus on the modulation of antigen recognition and ligand
specificity by the co-receptor CD8 (4). Based on existing exper-
imental data they formulate mathematical models that predict
dynamic variations of T-cell response specificity and magnitude as
a function of pMHCI/CD8 binding kinetics and of CD8 expression
levels on the cell surface, the latter phenomenon likely constituting
an adaptive mechanism tuning responsiveness at different devel-
opmental stages. On the subject of antigen specificity, Wooldridge
describes in details the extent of the cross-reactivity inherent to the
TCR and the consequent degeneracy of T-cell antigen recognition
(5). These parameters have clear implications when it comes to the
pre-clinical development of T-cell based therapies, especially with
respect to safety issues that relate to potential off-target effects.
Moving closer to translational research Burrows and Miles dis-
cuss the different parameters to consider when selecting TCRs
for use in cellular therapy or as biologics (6). Again this article
emphasizes the importance of assessing the antigen specificity and
degeneracy profiles of therapeutic TCR candidates both in syn-
geneic and allogeneic systems. On the flip side of the TCR/pMHC
interaction, Pentier et al. propose strategies to optimize T-cell
epitopes in the context of therapeutic vaccination, including the
design of synthetic antigen mimics that could circumvent the labile
nature of native l-amino-acid peptides (7). Also relevant to the
optimization of peptide ligands, Holland et al. provide fascinating
insights into peculiar- and little-appreciated aspects of MHC class
II epitope presentation, namely the influence of flanking residues
that extend outside the MHC groove, on the interaction between
the TCR and its antigen as well as T-cell activation (8).
A remarkable technological advance of molecular immunol-
ogy has been the use of recombinant pMHC molecules to monitor
T-cell responses by flow cytometry. Schmidt et al. review the devel-
opment of these tools in detail from their initial description as
monomeric reagents used to probe T-cell clones by photo-affinity
labeling to their popularization as tetramers and higher order mul-
timers for accurate and detailed ex vivo analysis of polyclonal T-cell
responses (9). The authors also give an extensive account of recent
technical improvements made in the manufacture of “switchable”
class I pMHC multimers for the isolation of “untouched” antigen-
specific T-cells and class II pMHC molecules and the challenges
inherent to antigen-specific analysis of CD4+ T-cell responses
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by flow cytometry. As further illustration of the great strides
made in pMHC technology Evavold and colleagues summarize the
groundbreaking 2-dimension adhesion frequency assay they have
developed and that allows monitoring TCR/pMHC interactions in
their natural membrane environment (10). They also define new
ways this technology can be used to advance our understanding of
T-cell biology, for instance the detection and characterization of
elusive CD4+ T-cells.
A large part of the Research Topic focuses on T-cell based cel-
lular cancer therapies, perhaps the most promising domain of
therapeutic application of T-cell biology at the moment. This
approach has seen recent remarkable clinical success and is cur-
rently actively pursued around the globe. Kerkar starts by giving
a general overview of T-cell based therapies for cancer and other
disease indications (11). In addition to classical T-cell re-direction
using viral vectors expressing TCRs or chimeric antigen receptors
(CARs) the author discusses different therapeutic strategies using
T-cells as vehicles such as the delivery of cytokines to diseased
tissues. Kunert et al. remind us of the recent clinical successes of
T-cell adoptive therapies by offering a comparative overview of
clinical trials evaluating different experimental therapies in devel-
opment, including immune checkpoint blocking antibodies and
small molecule inhibitors (12). The authors proceed to define what
parameters likely determine the success rates of TCR gene ther-
apy, from the choice of target antigens to the cues that influence
T-cell fitness or pre-conditioning patient treatment, and suggest
strategies to overcome current challenges in the field.
Since the vast majority of tumor-associated antigens are directly
derived from self proteins most naturally occurring peripheral
TCRs bind to tumor pMHC with low affinity compared to micro-
bial epitopes. Consequently, antigen receptor engineering that
seeks to optimize and improve the recognition of tumor epi-
topes by increasing the affinity of the TCR is an important
focus in the field of cancer cellular therapies. Stone and Kranz
review in detail the TCR affinity-optimization efforts to date,
mostly based on in vitro protein evolution platforms such as
yeast and phage display, highlighting the benefits of the approach
in terms of enhanced anti-tumor reactivity but also its pitfalls,
in particular risks of autoimmune adverse effects in the case of
high-affinity TCRs cross-reacting with non-tumor self epitopes
(13). The authors further suggest strategies to identify potential
off-target cross-reactive epitopes during the pre-clinical devel-
opment of affinity-optimized TCRs. On the same topic Zoete
et al. argue in favor of a rational, structure-guided approach
to TCR/pMHC affinity-optimization (14). The authors describe
their modus operandi to this endeavor, which is based on the
in silico modeling of mutations within the complementary deter-
mining region loops of the TCR based on solved and modeled
structures of TCR/pMHC complexes. An important take home
message of these articles is that affinity enhancement should be
within the physiological range of affinities observed for natural
TCRs as supra-normal affinities seem to both result in ineffi-
cient activation as well as enhanced cross-reactivity. However,
with respect to cross-reactivity, this view is somewhat counter-
balanced by the article of Cole et al. who report the first structure
of a high-affinity TCR generated by random mutagenesis and iso-
lated by phage display (15). This TCR only bears mutations within
the hypervariable CDR3β loop and owes its enhanced binding
properties to additional contacts with the peptide rather than the
MHC molecule, explaining the relative lack of increase in affinity
for known cross-reactive ligands compared to the index epitope.
Directed mutations that seek to mimic this design may be the way
forward for TCR affinity-optimization.
Even though the articles of this topic focus heavily on the use
of TCRs for cancer cellular therapy this shouldn’t play down the
promises of CARs, which have also shown spectacular clinical
results. This small injustice is repaired thanks to the article of
Hombach and Abken, who review recent CAR engineering princi-
ples intended to promote long-term persistence and functionality
of re-directed T-cells in vivo by triggering co-stimulatory signaling
pathways subsequent to antigen engagement (16).
In addition to receptor engineering, a complementary and
promising avenue to improve the efficacy of T-cell based cancer
cellular therapies lies in the inactivation of immune-suppressive
mediators of the tumor milieu. Recent clinical successes obtained
with blocking antibodies targeting CTLA-4 or PD-1 as monothera-
pies raise the question of whether combining such approaches with
T-cell adoptive transfer would provide additional clinical benefit,
as it is hoped it will with vaccines. In accordance, Rufer and col-
leagues discuss TCR affinity-optimization along with other poten-
tial therapeutic strategies that include targeting co-inhibitory
receptors with blocking monoclonal antibodies, impairing down-
stream inhibitory signaling and second messenger pathways with
small molecule inhibitors or activating co-stimulatory receptors
with agonistic antibodies (17). Generally speaking the combina-
tion of T-cell therapy with the inactivation of co-inhibitory recep-
tors expressed by T-cells is a recurrent theme in the articles of the
research topic and in the broader literature. The implementation
of such therapeutic interventions is also a matter of discussion.
Co-administration of blocking monoclonal antibodies or recom-
binant proteins with cellular therapies is usually the most popular
option. However, recent progress in genome engineering technolo-
gies offers new angles for co-inhibitory receptor inactivation in the
context of cellular therapies. Lloyd et al. briefly review the literature
on protein-guided and RNA-guided endonucleases as a means to
inactivate specific genes in human cells (18). They hypothesize that
the co-delivery of anti-tumor antigen receptors with genome edit-
ing agents targeting immune checkpoint receptor genes may rep-
resent a cost-efficient and safe way of improving cancer ACTs with-
out the need for combining different therapeutic modalities such
as the adoptive transfer of cells as well as the infusion of biologics.
In summary, these 18 articles give an overview of several themes
currently under investigation, and of their challenges, in the field
of human T-cell biology. It is noteworthy that a large part of the
Research Topic addresses applied aspects of T-cell immunology;
this might be an indication that decades of intense fundamen-
tal research might be about to pay off and translate into effective
treatments as well as viable commercial products.
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